Press Release: Novartis: New real--world data -2-

Novartis

138.00 EUR -2.47%

• Charts
• News
• Analysen

Kaufen Verkaufen

References

1. George DJ, et al. Real--world outcomes of [177Lu]Lu--PSMA--617 in

taxane--naïve patients with metastatic castration--resistant

prostate cancer (mCRPC): a PRECISION data platform analysis. Presented at

ASCO Genitourinary Cancers Symposium, February 26, 2026.

2. Wei XX, et al. Real--world effectiveness of systemic therapies after

[177Lu]Lu--PSMA--617 treatment in patients with metastatic

castration--resistant prostate cancer (mCRPC): a PRostatE Cancer dISease

observatION (PRECISION) data platform analysis. Presented at ASCO

Genitourinary Cancers Symposium, February 26--28, 2026.

3. National Comprehensive Cancer Network(R) (NCCN(R)) Guidelines. NCCN

Clinical Practice Guidelines in Oncology (NCCN Guidelines(R)) - Prostate

Cancer. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

4. George DJ, et al. Treatment utilization among patients with metastatic

hormone--sensitive prostate cancer (mHSPC) in real--world US settings: a

PRostatE Cancer dISease observatION (PRECISION) data platform analysis.

Presented at ASCO Genitourinary Cancers Symposium, February 26--28, 2026.

5. Sartor O, et al. Clinical outcomes among patients with metastatic

hormone--sensitive prostate cancer (mHSPC) in contemporary real--world US

clinical practice: a PRostatE Cancer dISease observatION (PRECISION) data

platform analysis. Presented at ASCO Genitourinary Cancers Symposium,

February 26--28, 2026.

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations Central

investor relations link: +41 61 324 7944

E-mail: investor.relations@novartis.com

(END) Dow Jones Newswires

February 24, 2026 07:15 ET (12:15 GMT)